Recombinant sclerostin inhibits bone formation in vitro and in a mouse model of sclerosteosis
Background: Sclerosteosis, a severe autosomal recessive sclerosing skeletal dysplasia characterised by excessive bone formation, is caused by absence of sclerostin, a negative regulator of bone formation that binds LRP5/6 Wnt co-receptors. Current treatment is limited to surgical management of sympt...
Main Authors: | Timothy Dreyer, Mittal Shah, Carl Doyle, Kevin Greenslade, Mark Penney, Paul Creeke, Apoorva Kotian, Hua Zhu Ke, Vinny Naidoo, Gill Holdsworth |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-07-01
|
Series: | Journal of Orthopaedic Translation |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2214031X21000413 |
Similar Items
-
A Novel Mutation in a Gene Causes Sclerosteosis in a Family of Mediterranean Origin
by: Aishah A. Ekhzaimy, et al.
Published: (2022-01-01) -
Identification of Compound Heterozygous Variants in LRP4 Demonstrates That a Pathogenic Variant outside the Third β-Propeller Domain Can Cause Sclerosteosis
by: Yentl Huybrechts, et al.
Published: (2021-12-01) -
Sclerostin and occlusion: A brief review
by: Pankaj Bansal, et al.
Published: (2015-01-01) -
The Role of Sclerostin in Bone Diseases
by: Elias S. Vasiliadis, et al.
Published: (2022-02-01) -
Expression of SOST/sclerostin in compressed periodontal ligament cells
by: Masae Ueda, et al.
Published: (2016-09-01)